tetano
Editor, Senior Moderator
Viruses. 2015 Sep 21;7(9):5133-5144.
[h=1]Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice.[/h] Cho S[SUP]1[/SUP], Youn HN[SUP]2[/SUP], Hoang PM[SUP]3[/SUP], Cho S[SUP]4[/SUP], Kim KE[SUP]5[/SUP], Kil EJ[SUP]6[/SUP], Lee G[SUP]7[/SUP], Cho MJ[SUP]8[/SUP], Hong J[SUP]9[/SUP], Byun SJ[SUP]10[/SUP], Song CS[SUP]2[/SUP], Lee S[SUP]11[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The antiviral effect of a catalytic RNA-hydrolyzing antibody, 3D8 scFv, for intranasal administration against avian influenza virus (H1N1) was described. The recombinant 3D8 scFv protein prevented BALB/c mice against H1N1 influenza virus infection by degradation of the viral RNA genome through its intrinsic RNA-hydrolyzing activity. Intranasal administration of 3D8 scFv (50 μg/day) for five days prior to infection demonstrated an antiviral activity (70% survival) against H1N1 infection. The antiviral ability of 3D8 scFv to penetrate into epithelial cells from bronchial cavity via the respiratory mucosal layer was confirmed by immunohistochemistry, qRT-PCR, and histopathological examination. The antiviral activity of 3D8 scFv against H1N1 virus infection was not due to host immune cytokines or chemokines, but rather to direct antiviral RNA-hydrolyzing activity of 3D8 scFv against the viral RNA genome. Taken together, our results suggest that the RNase activity of 3D8 scFv, coupled with its ability to penetrate epithelial cells through the respiratory mucosal layer, directly prevents H1N1 virus infection in a mouse model system.
[h=4]KEYWORDS:[/h] 3D8 scFv; antiviral effect; influenza virus; intranasal administration; nuclease activity; respiratory mucosal layer
PMID: 26402693 [PubMed - as supplied by publisher]
[h=1]Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice.[/h] Cho S[SUP]1[/SUP], Youn HN[SUP]2[/SUP], Hoang PM[SUP]3[/SUP], Cho S[SUP]4[/SUP], Kim KE[SUP]5[/SUP], Kil EJ[SUP]6[/SUP], Lee G[SUP]7[/SUP], Cho MJ[SUP]8[/SUP], Hong J[SUP]9[/SUP], Byun SJ[SUP]10[/SUP], Song CS[SUP]2[/SUP], Lee S[SUP]11[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The antiviral effect of a catalytic RNA-hydrolyzing antibody, 3D8 scFv, for intranasal administration against avian influenza virus (H1N1) was described. The recombinant 3D8 scFv protein prevented BALB/c mice against H1N1 influenza virus infection by degradation of the viral RNA genome through its intrinsic RNA-hydrolyzing activity. Intranasal administration of 3D8 scFv (50 μg/day) for five days prior to infection demonstrated an antiviral activity (70% survival) against H1N1 infection. The antiviral ability of 3D8 scFv to penetrate into epithelial cells from bronchial cavity via the respiratory mucosal layer was confirmed by immunohistochemistry, qRT-PCR, and histopathological examination. The antiviral activity of 3D8 scFv against H1N1 virus infection was not due to host immune cytokines or chemokines, but rather to direct antiviral RNA-hydrolyzing activity of 3D8 scFv against the viral RNA genome. Taken together, our results suggest that the RNase activity of 3D8 scFv, coupled with its ability to penetrate epithelial cells through the respiratory mucosal layer, directly prevents H1N1 virus infection in a mouse model system.
[h=4]KEYWORDS:[/h] 3D8 scFv; antiviral effect; influenza virus; intranasal administration; nuclease activity; respiratory mucosal layer
PMID: 26402693 [PubMed - as supplied by publisher]